rs121918386 — APOB APOB Arg2085Ter

When ApoB Is Cut Short — The APOB Stop Codon at Position 2085

Apolipoprotein B-100 (ApoB-100)¹¹ Apolipoprotein B-100 (ApoB-100)
The structural backbone of every LDL and VLDL particle; a single 4,536-amino-acid protein that must be assembled intact before each particle can leave the liver is among the largest proteins in the human body. The rs121918386 variant introduces a premature stop codon at amino acid 2085, producing a truncated protein roughly 46% the length of normal ApoB-100. In the lipoprotein assembly pathway, this is enough to prevent full LDL particle formation — driving LDL cholesterol levels far below population norms in heterozygous carriers and, in the extremely rare biallelic state, causing serious fat-soluble vitamin malabsorption.

The Mechanism

In the liver, each nascent VLDL particle requires one intact ApoB-100 molecule as its structural scaffold. The rs121918386 A allele changes codon 2085 from arginine (CGG) to a stop signal (TGA) at the coding level ²² Plus-strand allele A corresponds to c.6253C>T on the minus-strand APOB gene — the plus-strand G is the reference; A is the pathogenic alternate. The resulting truncated fragment — sometimes called ApoB-46 (representing 46% of the full-length protein) — lacks the C-terminal domains required for stable lipoprotein particle completion. Most truncated fragments this short are degraded intracellularly before secretion.

The truncation at position 2085 is notable relative to another key landmark: the ApoB-48 editing site at codon 2153. Full-length intestinal ApoB-48 (required for chylomicron assembly) is encoded by the first ~48% of the APOB mRNA. The 2085 truncation falls just upstream of this boundary, meaning heterozygous carriers retain full intestinal ApoB-48 production from their intact allele — fat absorption and chylomicron formation are normal at the heterozygous stage.

An unexpected consequence of this mutation is that apoB-100 secretion drops to roughly 25% of normal, not the 50% predicted from losing one functional allele³³ apoB-100 secretion drops to roughly 25% of normal, not the 50% predicted from losing one functional allele
Schonfeld 2003 — truncated apoB fragments suppress ApoB-100 secretion from the intact allele through a dominant-negative effect on endoplasmic reticulum lipidation. This amplified reduction explains the deeply suppressed LDL cholesterol seen in heterozygous carriers.

The Evidence

The cardiovascular implications of APOB truncating variants were quantified definitively by Peloso et al. (2019)⁴⁴ Peloso et al. (2019), who analysed rare protein-truncating variants in APOB across studies involving approximately 58,000 individuals. Carriers showed a 72% reduction in coronary heart disease risk (OR 0.28) — one of the largest protective effects documented for any single-gene variant against cardiovascular disease.

Farese et al. (1992)⁵⁵ Farese et al. (1992) documented that heterozygous APOB truncation carriers consistently show LDL cholesterol one-quarter to one-third of unaffected family members — a striking deviation from routine lipid panels that often triggers clinical investigation for secondary causes before the genetic basis is identified.

Welty (2020)⁶⁶ Welty (2020) synthesised data from 12 case-control studies and confirmed the hepatic risk in this condition: fatty liver, cirrhosis, and hepatocellular carcinoma have been reported in familial hypobetalipoproteinemia, primarily in biallelic disease, because lipid that cannot be packaged into VLDL accumulates in hepatocytes. Heterozygotes have roughly 5–10% risk of nonalcoholic hepatic steatosis.

This variant is extraordinarily rare: the A allele appears in approximately 23 of 1.4 million alleles in gnomAD v4 exomes, present predominantly in European-ancestry populations at an estimated frequency of ~0.0000172. Homozygosity is essentially absent in population data.

Practical Actions

For heterozygous carriers (AG genotype), the unexpected clinical picture is unexpectedly low LDL on routine testing — often triggering workup for secondary hypocholesterolaemia before the genetic cause is found. Once identified, the low-LDL profile is strongly cardioprotective. The key concerns are hepatic steatosis (in a minority of carriers) and the need to flag the genotype to any prescribing physician considering LDL-lowering therapy, since baseline LDL is already dramatically suppressed.

Published surveillance guidelines (Burnett, Hooper, and Hegele, GeneReviews 2021⁷⁷ Burnett, Hooper, and Hegele, GeneReviews 2021) recommend fasting lipid panels and liver function tests every 1–2 years for heterozygous carriers, with hepatic ultrasound every 3 years if transaminases are persistently elevated.

Interactions

rs121918386 shares its disease category — familial hypobetalipoproteinemia type 1 — with other APOB truncating variants, most notably rs121918384 (Val1856fs, a frameshift upstream of this stop codon). Compound heterozygotes carrying two different APOB loss-of-function alleles develop biallelic-equivalent disease with severe fat malabsorption, as each allele independently destroys ApoB-100 function. Within the broader lipid pathway, co-occurrence with PCSK9 gain-of-function variants (which further reduce LDL receptor clearance) or LDLR loss-of-function alleles could partially offset the hypocholesterolaemic phenotype — producing a paradoxically normal LDL despite carrying a hypobetalipoproteinemia allele.